阿那莫林主要治疗什么？

What does Anamorelin mainly treat? (Anamorelin) is a synthetic mimic of the N-terminal active core of ghrelin. It was developed by Novo Nordisk in 1999 and subsequently licensed by Ono and Helsinn. It is used to treat cachexia and anorexia in cancer patients. It is currently the only drug proven to alleviate the progression of cancer cachexia in multiple phase III clinical trials.

An article in 2015 reported the data results of two phase II clinical trials (NCTO0219817 and NCTO0267358). This summary report included a total of 82 patients (44 patients in the anamorelin group and 38 patients in the control group). The final number of patients who met the analysis criteria was 74 patients, who were randomly divided into the anamorelin 50 mg group and the placebo control group. In terms of adverse reactions, the most common grade 3 to 4 adverse events (related or unrelated to treatment) in the anamorelin group were fatigue (n=2), asthenia (n=2), atrial fibrillation (n=2) and dyspnea (n=2); in the placebo group, they were mainly pneumonia (n=3), anemia (n=2), thrombocytopenia (n=2), abdominal pain (n=2), anxiety (n=2) and dyspnea (n=2).

Currently, a series of Phase II and III clinical trials of the GHSR agonist Anamorelin conducted abroad have shown us that it has certain efficacy in improving patients' LBM, appetite, QoL and muscle strength, and the adverse reactions are tolerable. In the future, in addition to further in-depth observation and determination of the intervention timing and course of treatment of anamorelin on cachexia caused by different cancer types, it is also necessary to actively explore the best treatment model of anamorelin combined with other drug treatments or functional exercises, including conventional nutritional support treatment, progesterone drugs, glucocorticoid drugs, traditional Chinese medicine, traditional Chinese medicine rehabilitation physiotherapy, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.